Abstract
The effect of prenatal ASA ingestion on hemostasis was investigated in 59 maternal-neonate pairs. Group I consisted of 36 control pairs in whom a negative ASA drug history was substantiated by normal maternal and neonatal platelet aggregations and values for the prostaglandin byproduct malonyldialdehyde (MDA). Group II consisted of 16 pairs in whom a positive history for maternal ASA ingestion was confirmed by the expected abnormalities in platelet aggregations and MDA. Group III comprised 7 maternal-neonate pairs where maternal ASA ingestion occurred within 6 hours post partum. All groups were evaluated for hemostatic abnormalities. Maternal blood loss was considered excessive, if a drop of >10% between initial and discharge hemoglobin occurred (vaginal delivery), or >25% (C section). In Group I, no maternal hemostatic abnormalities were noted, although 1/34 neonates demonstrated facial ecchymoses. In 10/16 Group II pairs where maternal ASA ingestion had occurred 0-5 days prior to delivery, clinical evidence of bleeding occurred in 90% (9/10) of the infants, and 60% (6/10) of the mothers. In contrast, in 6/16 Group II pairs, where ASA ingestion had occurred 6-10 days prior to delivery, no abnormalities were found. Group III infants were normal, although 57% (4/7) mothers in this group bled abnormally. ASA ingested in the 5 days prior to delivery, or immediately post partum, is associated with hemostatic abnormalities in both mother and neonate.
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stuart, M., Gross, S., Graeber, J. et al. 667 THE EFFECT OF PRENATAL ACETYL SALICYLIC ACID (ASA) INGESTION ON MATERNAL AND NEONATAL HEMOSTASIS. Pediatr Res 12 (Suppl 4), 475 (1978). https://doi.org/10.1203/00006450-197804001-00672
Issue date:
DOI: https://doi.org/10.1203/00006450-197804001-00672
